查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1979983

人工智慧神經診斷市場預測：至 2034 年—按產品、技術、應用、最終用戶和地區分類的全球分析

AI Neurodiagnostics Market Forecasts to 2034 - Global Analysis By Product, Technology, Application, End User and Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的研究，預計到 2026 年，全球 AI 神經診斷市場將達到 182 億美元，並在預測期內以 4.5% 的複合年成長率成長，到 2034 年達到 259 億美元。

人工智慧神經診斷是指利用人工智慧分析腦部相關數據並偵測神經系統疾病的技術。透過處理掃描影像、生物訊號和患者記錄，人工智慧系統可以識別與失智症、失智症和中風等疾病相關的模式。這些工具提高了醫生診斷的準確性和速度，有助於最佳化治療方案並改善患者預後。透過提供預測性見解並減少人為錯誤，這項技術增強了傳統方法，代表了醫學領域的一項前景廣闊的進步，融合了神經科學和機器學習。

神經系統疾病盛行率上升

阿茲海默症、帕金森氏症、癲癇和中風等神經系統疾病發病率的不斷上升，是人工智慧神經診斷市場的主要成長要素。全球人口老化和生活方式相關的風險因素正在擴大需要先進診斷解決方案的患者群體。對早期準確檢測的需求促使醫療機構採用人工智慧驅動的神經影像和預測分析工具。這些技術在提高診斷準確性的同時，也能縮短影像解讀時間。此外，不斷上漲的醫療成本和公眾意識的提高也在推動市場擴張。因此，神經系統疾病負擔的加重正在顯著加速人工智慧神經診斷技術的應用。

臨床檢驗及核准延誤

漫長的臨床檢驗過程和監管核准要求對商業化構成重大障礙。基於人工智慧的神經系統診斷解決方案必須透過廣泛的測試來證明其高精度、高重複性和安全性。監管機構制定了嚴格的合規標準，並延長了產品上市時間。此外，不斷發展的人工智慧管治框架也為開發者帶來了不確定性。小規模公司在漫長的檢驗週期中往往面臨沉重的財務負擔。因此，儘管技術取得了顯著進步，但核准延遲和複雜的認證流程阻礙了產品快速進入市場。

疾病早期檢測平台

新興的人工智慧驅動型早期檢測平台蘊藏著變革性的成長機會。先進的演算法能夠在臨床症狀出現之前，識別神經影像數據中細微的生物標記。在預防性醫療策略的推動下，醫療服務提供者正優先考慮能夠實現主動介入的工具。與穿戴式裝置和電子健康記錄的整合提高了預測模型的準確性。製藥公司也正在利用這些平台最佳化臨床試驗。隨著醫療體係向價值導向型醫療模式轉型，早期檢測能力蘊藏著巨大的商業性和臨床潛力。

資料隱私合規風險

資料隱私法規對人工智慧神經診斷系統的部署構成重大威脅。這些系統依賴大規模的患者資料集，其中包括敏感的神經影像記錄。諸如 HIPAA 和 GDPR 等嚴格的資料保護法要求企業建立嚴密的合規機制。違規行為可能導致經濟處罰和聲譽損害。此外，跨境資料傳輸的限制也使跨國公司的營運變得更加複雜。因此，網路安全漏洞和監管風險仍然是參與企業市場時面臨的持續挑戰。

新冠疫情的影響：

新冠疫情初期，由於就診量減少和選擇性篩檢測試延遲，神經學診斷流程受到干擾。由於醫療系統優先保障急診，人工智慧解決方案的應用一度放緩。然而，疫情加速了數位化醫療轉型和遠距離診斷能力的提升。在醫護人員短缺的情況下，遠距神經病學和人工智慧輔助影像診斷的重要性日益凸顯。醫療IT基礎設施投資的增加進一步推動了人工智慧的整合。疫情後的復甦正在增強對自動化、可擴展的神經系統診斷平台的長期需求。

在預測期內，基於人工智慧的神經影像軟體領域預計將佔據最大的市場佔有率。

在預測期內，基於人工智慧的神經影像軟體預計將佔據最大的市場佔有率。這些解決方案能夠以極高的精確度和速度分析MRI、CT和PET掃描影像。醫院和診斷中心對自動化影像分析的日益依賴，鞏固了該領域的領先地位。隨著影像檢查量的增加，臨床醫生正在尋求工作流程最佳化工具。演算法的不斷改進提高了腫瘤、病變和退化性病變的檢測準確性。只要影像檢查在神經系統疾病診斷中繼續發揮核心作用，該領域在收入方面就將保持主導。

預計在預測期內，深度學習和神經網路領域將實現最高的複合年成長率。

在預測期內，深度學習和神經網路領域預計將呈現最高的成長率。先進的神經網路架構能夠對複雜的腦部資料進行卓越的模式識別和異常檢測。隨著運算能力的提升和大規模標註資料集數量的成長，其效能能力也不斷增強。這些模型有助於預測分析和疾病進展建模。合作研究進一步加速了創新。因此，深度學習技術已成為人工智慧神經診斷市場中成長最快的技術基礎。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率。該地區強大的醫療保健基礎設施和人工智慧驅動型醫療技術的高普及率是其主導地位的基石。強勁的研發投入和領先的人工智慧醫療公司的存在正在加速商業化進程。有利的報銷政策進一步促進了人工智慧技術融入臨床工作流程。此外，神經系統疾病盛行率的不斷上升也增強了市場需求。隨著創新生態系統的日趨成熟，北美將繼續成為重要的收入來源。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率。醫療保健的快速數位化和醫院網路的擴張正在推動該地區的成長。各國政府正在加大對人工智慧創新和醫學影像基礎設施的投資。在患者數量激增和人們對神經系統疾病意識提升的推動下，對可擴展診斷技術的需求正在加速成長。在新興經濟體，經濟高效的人工智慧平台正被廣泛採用，以應對專科醫生短缺的問題。因此，亞太地區脫穎而出，成為成長最快的區域市場。

免費客製化服務：

購買此報告的客戶可以選擇以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 主要參與者（最多3家公司）的SWOT分析
  • 區域細分
    • 主要國家的市場估算和預測，以及根據客戶需求量身定做的複合年成長率（註：需要進行可行性測試）。
  • 競爭性標竿分析
    • 根據主要參與者的產品系列、地理覆蓋範圍和策略聯盟進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要企業市佔率分析
  • 產品基準評效和效能比較

第5章 全球人工智慧神經診斷市場：按產品分類

  • 基於人工智慧的神經影像軟體
  • 腦電圖分析平台
  • 腦監測系統
  • 臨床決策支援系統
  • 基於雲端的神經學診斷平台
  • 即時神經學診斷設備
  • 穿戴式腦部監測設備

第6章 全球人工智慧神經診斷市場：依技術分類

  • 機器學習演算法
  • 深度學習與神經網路
  • 自然語言處理
  • 電腦視覺在神經影像學的應用
  • 巨量資料分析
  • 雲端運算和邊緣人工智慧運算

第7章 全球人工智慧神經診斷市場：按應用分類

  • 癲癇偵測
  • 阿茲海默症診斷
  • 帕金森氏症評估
  • 中風偵測與監測
  • 創傷性腦損傷（TBI）分析
  • 腦腫瘤的識別

第8章 全球人工智慧神經診斷市場：按最終用戶分類

  • 醫院和神經科科診所
  • 診斷影像中心
  • 研究和學術機構
  • 遠端醫療提供者
  • 門診手術中心
  • 製藥公司

第9章 全球人工智慧神經診斷市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第10章 戰略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第11章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第12章：公司簡介

  • GE HealthCare Technologies Inc.
  • Siemens Healthineers AG
  • Koninklijke Philips NV
  • Canon Medical Systems Corporation
  • Fujifilm Holdings Corporation
  • Medtronic plc
  • Natus Medical Incorporated
  • Nihon Kohden Corporation
  • Compumedics Limited
  • Neurosoft LLC
  • BrainScope Company, Inc.
  • Butterfly Network, Inc.
  • iSchemaView, Inc.
  • Qure.ai Technologies Pvt. Ltd.
  • Aidoc Medical Ltd.
  • IBM Watson Health
  • Ceribell, Inc.
  • Advanced Brain Monitoring, Inc.
Product Code: SMRC34146

According to Stratistics MRC, the Global AI Neurodiagnostics Market is accounted for $18.2 billion in 2026 and is expected to reach $25.9 billion by 2034 growing at a CAGR of 4.5% during the forecast period. AI neurodiagnostics refers to the use of artificial intelligence to analyze brain-related data for detecting neurological conditions. By processing scans, signals, and patient records, AI systems can identify patterns linked to disorders such as epilepsy, dementia, or stroke. These tools assist doctors in making faster and more accurate diagnoses, improving treatment planning and patient outcomes. The technology enhances traditional methods by offering predictive insights and reducing human error, making it a promising advancement in healthcare that bridges neuroscience and machine learning.

Market Dynamics:

Driver:

Rising neurological disorder prevalence

The increasing incidence of neurological disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, and stroke is a primary growth catalyst for the AI Neurodiagnostics Market. Aging global demographics and lifestyle-related risk factors are expanding the patient pool requiring advanced diagnostic solutions. Fueled by the need for early and accurate detection, healthcare providers are adopting AI-enabled neuroimaging and predictive analytics tools. These technologies enhance diagnostic precision while reducing interpretation time. Moreover, rising healthcare expenditure and awareness campaigns further support market expansion. Consequently, growing neurological disease burden significantly accelerates AI neurodiagnostic adoption.

Restraint:

Clinical validation and approval delays

Lengthy clinical validation processes and regulatory approval requirements present substantial barriers to commercialization. AI-based neurodiagnostic solutions must demonstrate high accuracy, reproducibility, and safety through extensive trials. Regulatory agencies impose strict compliance standards, prolonging time-to-market. Additionally, evolving AI governance frameworks create uncertainty for developers. Smaller firms often face financial strain during prolonged validation cycles. Therefore, delayed approvals and complex certification pathways restrain rapid market penetration despite strong technological advancements.

Opportunity:

Early-stage disease detection platforms

Emerging AI-powered early detection platforms offer transformative growth opportunities. Advanced algorithms can identify subtle biomarkers in neuroimaging data before clinical symptoms manifest. Spurred by preventive healthcare strategies, providers are prioritizing tools that enable proactive intervention. Integration with wearable devices and electronic health records enhances predictive modeling accuracy. Pharmaceutical companies also leverage these platforms for clinical trial optimization. As healthcare systems shift toward value-based care, early-stage detection capabilities create substantial commercial and clinical potential.

Threat:

Data privacy compliance risks

Data privacy regulations pose a critical threat to AI neurodiagnostic deployment. These systems rely on large-scale patient datasets, including sensitive neurological imaging records. Stringent data protection laws such as HIPAA and GDPR mandate rigorous compliance frameworks. Non-compliance can result in financial penalties and reputational damage. Additionally, cross-border data transfer restrictions complicate multinational operations. Consequently, cybersecurity vulnerabilities and regulatory risks remain persistent challenges for market participants.

Covid-19 Impact:

The COVID-19 pandemic initially disrupted neurological diagnostic procedures due to reduced hospital visits and deferred elective screenings. Healthcare systems prioritized emergency care, temporarily slowing AI solution adoption. However, the pandemic accelerated digital health transformation and remote diagnostic capabilities. Tele-neurology and AI-assisted imaging interpretation gained traction amid workforce shortages. Increased investment in healthcare IT infrastructure further supported AI integration. Post-pandemic recovery has strengthened long-term demand for automated, scalable neurodiagnostic platforms.

The AI-based neuroimaging softwaresegment is expected to be the largest during the forecast period

The AI-based neuroimaging software segment is expected to account for the largest market share during the forecast period. These solutions analyze MRI, CT, and PET scans with enhanced accuracy and speed. Growing reliance on automated imaging interpretation in hospitals and diagnostic centers underpins segment dominance. Influenced by rising imaging volumes, clinicians seek workflow optimization tools. Continuous algorithm refinement improves detection of tumors, lesions, and degenerative patterns. As imaging remains central to neurological diagnosis, this segment sustains revenue leadership.

The deep learning & neural networkssegment is expected to have the highest CAGR during the forecast period

Over the forecast period, the deep learning & neural networks segment is predicted to witness the highest growth rate. Advanced neural architectures enable superior pattern recognition and anomaly detection in complex brain data. Propelled by increasing computational power and large annotated datasets, performance capabilities continue to expand. These models facilitate predictive analytics and disease progression modeling. Research collaborations further accelerate innovation. Consequently, deep learning technologies represent the fastest-growing technological backbone within the AI Neurodiagnostics Market.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share. Robust healthcare infrastructure and high adoption of AI-driven medical technologies support regional dominance. Strong R&D investments and presence of leading AI healthcare firms accelerate commercialization. Favorable reimbursement policies further encourage integration into clinical workflows. Additionally, increasing neurological disease prevalence strengthens demand. As innovation ecosystems mature, North America remains the primary revenue contributor.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR. Rapid healthcare digitization and expanding hospital networks drive regional growth. Governments are investing in AI innovation and medical imaging infrastructure. Propelled by large patient populations and rising neurological awareness, demand for scalable diagnostics is accelerating. Emerging economies are adopting cost-efficient AI platforms to address specialist shortages. Therefore, Asia Pacific stands out as the fastest-growing regional market.

Key players in the market

Some of the key players in AI Neurodiagnostics Market include GE HealthCare Technologies Inc., Siemens Healthineers AG, Koninklijke Philips N.V., Canon Medical Systems Corporation, Fujifilm Holdings Corporation, Medtronic plc, Natus Medical Incorporated, Nihon Kohden Corporation, Compumedics Limited, Neurosoft LLC, BrainScope Company, Inc., Butterfly Network, Inc., iSchemaView, Inc., Qure.ai Technologies Pvt. Ltd., Aidoc Medical Ltd., IBM Watson Health, Ceribell, Inc., and Advanced Brain Monitoring, Inc.

Key Developments:

In February 2026, Qure.ai Technologies Pvt. Ltd. announced enhancements to its AI stroke triage platform, enabling faster detection of large vessel occlusions in emergency departments, improving time-to-treatment outcomes.

In January 2026, Aidoc Medical Ltd. launched its AI Neuro Suite expansion, adding modules for intracranial hemorrhage detection and workflow prioritization, strengthening its role in acute care diagnostics.

In November 2025, Butterfly Network, Inc. introduced AI-powered portable brain imaging capabilities on its handheld ultrasound devices, targeting point-of-care neurodiagnostics in rural and resource-limited settings.

Products Covered:

  • AI-Based Neuroimaging Software
  • EEG Analytics Platforms
  • Brain Monitoring Systems
  • Clinical Decision Support Systems
  • Cloud-Based Neurodiagnostic Platforms
  • Point-of-Care Neurodiagnostic Devices
  • Wearable Brain Monitoring Devices

Technologies Covered:

  • Machine Learning Algorithms
  • Deep Learning & Neural Networks
  • Natural Language Processing
  • Computer Vision in Neuroimaging
  • Big Data Analytics
  • Cloud & Edge AI Computing

Applications Covered:

  • Epilepsy Detection
  • Alzheimer's Disease Diagnosis
  • Parkinson's Disease Assessment
  • Stroke Detection & Monitoring
  • Traumatic Brain Injury (TBI) Analysis
  • Brain Tumor Identification

End Users Covered:

  • Hospitals & Neurology Clinics
  • Diagnostic Imaging Centers
  • Research & Academic Institutes
  • Telemedicine Providers
  • Ambulatory Surgical Centers
  • Pharmaceutical Companies

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global AI Neurodiagnostics Market, By Product

  • 5.1 AI-Based Neuroimaging Software
  • 5.2 EEG Analytics Platforms
  • 5.3 Brain Monitoring Systems
  • 5.4 Clinical Decision Support Systems
  • 5.5 Cloud-Based Neurodiagnostic Platforms
  • 5.6 Point-of-Care Neurodiagnostic Devices
  • 5.7 Wearable Brain Monitoring Devices

6 Global AI Neurodiagnostics Market, By Technology

  • 6.1 Machine Learning Algorithms
  • 6.2 Deep Learning & Neural Networks
  • 6.3 Natural Language Processing
  • 6.4 Computer Vision in Neuroimaging
  • 6.5 Big Data Analytics
  • 6.6 Cloud & Edge AI Computing

7 Global AI Neurodiagnostics Market, By Application

  • 7.1 Epilepsy Detection
  • 7.2 Alzheimer's Disease Diagnosis
  • 7.3 Parkinson's Disease Assessment
  • 7.4 Stroke Detection & Monitoring
  • 7.5 Traumatic Brain Injury (TBI) Analysis
  • 7.6 Brain Tumor Identification

8 Global AI Neurodiagnostics Market, By End User

  • 8.1 Hospitals & Neurology Clinics
  • 8.2 Diagnostic Imaging Centers
  • 8.3 Research & Academic Institutes
  • 8.4 Telemedicine Providers
  • 8.5 Ambulatory Surgical Centers
  • 8.6 Pharmaceutical Companies

9 Global AI Neurodiagnostics Market, By Geography

  • 9.1 North America
    • 9.1.1 United States
    • 9.1.2 Canada
    • 9.1.3 Mexico
  • 9.2 Europe
    • 9.2.1 United Kingdom
    • 9.2.2 Germany
    • 9.2.3 France
    • 9.2.4 Italy
    • 9.2.5 Spain
    • 9.2.6 Netherlands
    • 9.2.7 Belgium
    • 9.2.8 Sweden
    • 9.2.9 Switzerland
    • 9.2.10 Poland
    • 9.2.11 Rest of Europe
  • 9.3 Asia Pacific
    • 9.3.1 China
    • 9.3.2 Japan
    • 9.3.3 India
    • 9.3.4 South Korea
    • 9.3.5 Australia
    • 9.3.6 Indonesia
    • 9.3.7 Thailand
    • 9.3.8 Malaysia
    • 9.3.9 Singapore
    • 9.3.10 Vietnam
    • 9.3.11 Rest of Asia Pacific
  • 9.4 South America
    • 9.4.1 Brazil
    • 9.4.2 Argentina
    • 9.4.3 Colombia
    • 9.4.4 Chile
    • 9.4.5 Peru
    • 9.4.6 Rest of South America
  • 9.5 Rest of the World (RoW)
    • 9.5.1 Middle East
      • 9.5.1.1 Saudi Arabia
      • 9.5.1.2 United Arab Emirates
      • 9.5.1.3 Qatar
      • 9.5.1.4 Israel
      • 9.5.1.5 Rest of Middle East
    • 9.5.2 Africa
      • 9.5.2.1 South Africa
      • 9.5.2.2 Egypt
      • 9.5.2.3 Morocco
      • 9.5.2.4 Rest of Africa

10 Strategic Market Intelligence

  • 10.1 Industry Value Network and Supply Chain Assessment
  • 10.2 White-Space and Opportunity Mapping
  • 10.3 Product Evolution and Market Life Cycle Analysis
  • 10.4 Channel, Distributor, and Go-to-Market Assessment

11 Industry Developments and Strategic Initiatives

  • 11.1 Mergers and Acquisitions
  • 11.2 Partnerships, Alliances, and Joint Ventures
  • 11.3 New Product Launches and Certifications
  • 11.4 Capacity Expansion and Investments
  • 11.5 Other Strategic Initiatives

12 Company Profiles

  • 12.1 GE HealthCare Technologies Inc.
  • 12.2 Siemens Healthineers AG
  • 12.3 Koninklijke Philips N.V.
  • 12.4 Canon Medical Systems Corporation
  • 12.5 Fujifilm Holdings Corporation
  • 12.6 Medtronic plc
  • 12.7 Natus Medical Incorporated
  • 12.8 Nihon Kohden Corporation
  • 12.9 Compumedics Limited
  • 12.10 Neurosoft LLC
  • 12.11 BrainScope Company, Inc.
  • 12.12 Butterfly Network, Inc.
  • 12.13 iSchemaView, Inc.
  • 12.14 Qure.ai Technologies Pvt. Ltd.
  • 12.15 Aidoc Medical Ltd.
  • 12.16 IBM Watson Health
  • 12.17 Ceribell, Inc.
  • 12.18 Advanced Brain Monitoring, Inc.

List of Tables

  • Table 1 Global AI Neurodiagnostics Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global AI Neurodiagnostics Market Outlook, By Product (2023-2034) ($MN)
  • Table 3 Global AI Neurodiagnostics Market Outlook, By AI-Based Neuroimaging Software (2023-2034) ($MN)
  • Table 4 Global AI Neurodiagnostics Market Outlook, By EEG Analytics Platforms (2023-2034) ($MN)
  • Table 5 Global AI Neurodiagnostics Market Outlook, By Brain Monitoring Systems (2023-2034) ($MN)
  • Table 6 Global AI Neurodiagnostics Market Outlook, By Clinical Decision Support Systems (2023-2034) ($MN)
  • Table 7 Global AI Neurodiagnostics Market Outlook, By Cloud-Based Neurodiagnostic Platforms (2023-2034) ($MN)
  • Table 8 Global AI Neurodiagnostics Market Outlook, By Point-of-Care Neurodiagnostic Devices (2023-2034) ($MN)
  • Table 9 Global AI Neurodiagnostics Market Outlook, By Wearable Brain Monitoring Devices (2023-2034) ($MN)
  • Table 10 Global AI Neurodiagnostics Market Outlook, By Technology (2023-2034) ($MN)
  • Table 11 Global AI Neurodiagnostics Market Outlook, By Machine Learning Algorithms (2023-2034) ($MN)
  • Table 12 Global AI Neurodiagnostics Market Outlook, By Deep Learning & Neural Networks (2023-2034) ($MN)
  • Table 13 Global AI Neurodiagnostics Market Outlook, By Natural Language Processing (2023-2034) ($MN)
  • Table 14 Global AI Neurodiagnostics Market Outlook, By Computer Vision in Neuroimaging (2023-2034) ($MN)
  • Table 15 Global AI Neurodiagnostics Market Outlook, By Big Data Analytics (2023-2034) ($MN)
  • Table 16 Global AI Neurodiagnostics Market Outlook, By Cloud & Edge AI Computing (2023-2034) ($MN)
  • Table 17 Global AI Neurodiagnostics Market Outlook, By Application (2023-2034) ($MN)
  • Table 18 Global AI Neurodiagnostics Market Outlook, By Epilepsy Detection (2023-2034) ($MN)
  • Table 19 Global AI Neurodiagnostics Market Outlook, By Alzheimer's Disease Diagnosis (2023-2034) ($MN)
  • Table 20 Global AI Neurodiagnostics Market Outlook, By Parkinson's Disease Assessment (2023-2034) ($MN)
  • Table 21 Global AI Neurodiagnostics Market Outlook, By Stroke Detection & Monitoring (2023-2034) ($MN)
  • Table 22 Global AI Neurodiagnostics Market Outlook, By Traumatic Brain Injury (TBI) Analysis (2023-2034) ($MN)
  • Table 23 Global AI Neurodiagnostics Market Outlook, By Brain Tumor Identification (2023-2034) ($MN)
  • Table 24 Global AI Neurodiagnostics Market Outlook, By End User (2023-2034) ($MN)
  • Table 25 Global AI Neurodiagnostics Market Outlook, By Hospitals & Neurology Clinics (2023-2034) ($MN)
  • Table 26 Global AI Neurodiagnostics Market Outlook, By Diagnostic Imaging Centers (2023-2034) ($MN)
  • Table 27 Global AI Neurodiagnostics Market Outlook, By Research & Academic Institutes (2023-2034) ($MN)
  • Table 28 Global AI Neurodiagnostics Market Outlook, By Telemedicine Providers (2023-2034) ($MN)
  • Table 29 Global AI Neurodiagnostics Market Outlook, By Ambulatory Surgical Centers (2023-2034) ($MN)
  • Table 30 Global AI Neurodiagnostics Market Outlook, By Pharmaceutical Companies (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.